U.S. Markets close in 3 hrs 29 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
634.19-12.32 (-1.91%)
As of 12:31PM EDT. Market open.
Sign in to post a message.
  • W
    Walter
    Many people are seeking for stability in this unstable crypto space and A lot of people are wondering if now is a good time to buy because of where the price is at right now . I'd say it's outrightly wrong to just sit back hold and wait maybe incur some losses along the line , that's a wrong mindset for an investor because as an investor finding ways to always increase and stack up more coins thereby making proflts should be the way of life that being said , the market is still all about BTC at the moment and I'll advise current investors and newbies to take advantage of the Mr Steve program , an establishment that handles people who lack understanding on how maneuver the crypto space , to help them recover loss from the crash and also accumulate more positive returns , with their program i went from having 1.4btc to 9btc in just 9 weeks.

    All you'd need to do is send Steve a message
    whats<<<>>App + 1 ( 8 1 3 ) 6 8 3 ‑ 6 3 1 0 OR on Te** le* gram @ ( SteveFX01 )
    Bullish
  • J
    Juan
    Regeneron has 9 major drugs in phase 3 trials. Phase 3 drugs are passed 68 % of the time. Some of these trials are in the later stage. You have all these revenue generations about to enter the market while the ones active now are finding off label uses. Cancer drugs are hard to get to phase 3 and are very lucrative once they enter legal use status
  • t
    theubiquitousman
    word is getting out, monoclonal antibodies are the way to treat covid. vaccines just don't seem to be
    effectrive long term. REGN at PE of 12, minimal debt. could be a double from here. Just my opinions.
  • c
    cynthia
    Looking at directed trade activity on REGN, there are NO buyers. NO block trades. Drips and drabs. Very few shares on the sell side and NO shares on the buy side drive this stock down in double digits. Daily. I've been holding off but I think now is the time to sell some covered calls. November 700s for $9.
  • J
    Juan
    Libtayo's lung cancer phase 3 trials surpassed expectations. Unlike Keytruda it works in squamous cell lung cancer and survival rate was longer.
  • t
    theubiquitousman
    WHO recommends monoclonal antibody cocktail that REGN supplies and stock drops $7.5. Go figure
    Selling at a 12 PE with minimal debt. Good pipeline too. Go figure.
  • h
    hoekzema
    I heard about REGN the other day on (http://Stocks-tracker.com). It’s looking like an interesting play.
  • W
    Wealthy Detective YT
    Just provided an update on Regeneron, the largest position in my million dollars portfolio. Let me know what you think. I'm here for the long term, really like the company (NOT INVESTMENT ADVICE).
    https://youtu.be/sqxqNM5ijRY
    ��SUBSCRIBE for more: http://www.youtube.com/channel/UCi-afL7crlycyGqJ2QssIsw?sub_confirmation=1�What do you think about the MILLION DOLLARS Portfolio? Do...
    ��SUBSCRIBE for more: http://www.youtube.com/channel/UCi-afL7crlycyGqJ2QssIsw?sub_confirmation=1�What do you think about the MILLION DOLLARS Portfolio? Do...
    www.youtube.com
  • R
    Rex
    Once again positive news comes out and the stock sells off. At least it's consistent.
  • S
    SaberMaven
    A stock split might send a signal of management confidence and boost the PE.
  • T
    Taos
    Thanks to Regeneron executives for deciding to sell 1.4 million initial doses of monoclonal antibody treatments to the Federal dept of health and human services. An executive at Regeneron stated "deliveries" will start in Sept this year (now). That means that available doses are off the hospital/clinic shelves and en route to a HHS storage facility. In my state there was an article yesterday "regeneron" in limited supply at hospitals throughout the state. Thanks Regeneron for taking a large percentage of your production volume away from the states now when the public needs it the most. What does it say about china joe's care for the public that his cronies have been ordered to "take inventory" in govt storage of the most effective medicinal therapeutic for covid? Ever heard the term population reduction?
    Bearish
  • O
    O-Behave
    $BIIB conversation
    $BIIB Biogen initiated with a Buy at Needham TODAY. They couldn't resist these EXTREMELY OVERSOLD prices. So much for the doom and gloom. $BIIB is trading at levels it was trading at BEFORE it received FDA approval. On that day it ran to $468 in a flash. In fact it was halted, the market makers and institutions loaded and OPENED it in the high $400s. Today it's trading as if there was no FDA approval! To add to this insanity. IT JUST GOT FDA APPROVAL ON MONDAY for another drug and went under the radar because of the stock market crash on Monday. So $BIIB is trading at levels BEFORE TWO FDA approvals...TWO! Institutions and big pocket investors are loading this heavy TRUST ME. $PFE $NOVN $JNJ $REGN $MRK $LLY $MRNA all savy/experienced biotech traders should be loading the boat here. Did you see the relentless BUYS into close and afterhours? There was a dark pool buy worth $48 million today. Keep sleeping 😴
    Bullish
  • 6
    66 traveler
    The stock should have been UP at least 5%. There is so much value in this stock at this price. MRNA, ZM or BNTX are jokes compared to REGN. Investing has become gambling.
    Bullish
  • H
    Humble Warrior
    Told you couple of weeks ago, big news coming this month. 3 billion contract. Expect the price back up to $700.
    Bullish
  • s
    steven
    Many people on this platform write to the effect that the market hates this stock and that the price should be higher. As a long time holder (fifteen years plus), I can say that I honestly believe that it is manipulated by large institutional holders. They buy and sell in waves. They all know that this is a strong company heading up but they make a tremendous amount of money by letting it run up on buying by large institutions and then sell in waves. It has happened again and again over the last two decades.
  • r
    radbrad311
    #6 From the COVID Plan:

    Getting Life-Saving Monoclonal Antibody Treatment to Those Who Need It
    The United States government shipped an average of approximately 100,000 doses of monoclonal antibodies per week across July and August. The Administration will increase the average weekly pace of shipments of free monoclonal antibody treatment to states by a further 50% in September, continuing to accelerate the federal government’s efforts to deliver lifesaving COVID-19 treatment. Monoclonal antibody treatments have been shown to reduce the risk of hospitalization by up to 70% for unvaccinated people at risk of developing severe disease. As hospital systems experience increased COVID-19 cases, many have identified monoclonal antibody treatment as a key tool to improve health outcomes, prevent hospitalizations and reduce the strain on overburdened hospitals.
  • H
    Humble Warrior
    Quite frankly, after a recent runup in last 2 months, I am happy to see SP consolidating around $675 ± 15 to form a solid base.
    Those who wants to get excited about future of REGN, highly recommend going through corporate presentation available on investors section on their website. Sooooooo much coming down the line in next 4-5 years. I can honestly see this easily reaching $1500 SP, though not sure about that time it will take to reach there. But, it will be there.
    Bullish
  • r
    ryan
    As of August 2020, Ethereum is secured via the Ethash proof-of-work algorithm, belonging to the Keccak family of hash functions.
    There are plans, however, to transition the network to a proof-of-stake algorithm tied to the major Ethereum 2.0 update, which launched in late 2020
  • R
    Rex
    This stock must have set the record for sell short at the open and cover at the close to make a daily profit. Like clockwork.
  • R
    Richard
    After reaching overbought in June, REGN worked off the overbought in July by trading in a range of 574-589. In August, the stock reached overbought again and likely will spend September working off the overbought trading in a range of 663-680. That should provide the base to launch the next leg up. Estimates should be raised to $45 average for 2022, and the p/e should expand to 20x, yielding a share price of $900 in the next 12 months.